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Acute renal failure (ARF) is a relatively frequent complication associated with
heart transplantation. It develops in the first few days postoperatively and is
characterized by oliguria withlaboratory andurinary indices typical ofpre-renal
azotemia. Cyclosporine, especially with higherdoses, is one ofthe many factors
which play an integral part in the nephrotoxicity following cardiac transplant.
Poor preoperative renal function and perioperative hemodynamic compromise
may also contribute to ARF. The actual incidence ofARF now encountered by
transplant centers may be lower than previously reported, the result of lower
cyclosporine doses. Currently, management is entirely supportive, but novel
therapeutic approaches with atrial natriuretic peptide-like substances are being
explored. A case illustrating the typical clinical presentation ofARF after heart
transplant will be presented and the clinical features will be reviewed.
INTRODUCTION
Cardiac transplantation has been used since 1967 as a successful therapy for
intractable heart failure. Subsequently, the number of heart transplants performed yearly
continues to increase. As with other open-heart surgery, acute renal failure (ARF)b has
been a well-recognized postoperative complication of cardiac transplantation [1-5].
However, the incidence ofARF associated with cardiac transplant surgery is greater than
that seen with non-transplant heart surgery. The excessive incidence of ARF in cardiac
transplantation is, in part, explained by the nephrotoxic effects ofcyclosporine. We here-
in describe a case illustrating the typical clinical features ofARF following heart trans-
plantation, and discuss etiology, clinical course and management. In particular, we com-
pare cardiac-transplant associated ARF to the ARF following other open-heart surgical
procedures.
CASE REPORT
A 62 yearold Caucasian male with apriorhistory ofcoronary artery bypass 12 yr ago
and myocardial infarction 8 yr ago, suffered a large anterolateral and inferior myocardial
infarction complicated by severely impaired myocardial function with adepressed cardiac
output. The patient failed tissue plasminogen activator therapy and percutaneous translu-
minal angioplasty, and was deemed unsuitable forsurgical revascularization. An intra-aor-
tic balloon pump (IABP) was required to maintain hemodynamic stability.
On his fourth hospital day, he was transferred to Yale-New Haven Hospital for car-
diac transplantation evaluation. His BUN and creatinine were 24 mg/dl and 1.2 mg/dl,
respectively, at the time of transfer. He remained on the IABP. Medications included
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heparin, 1500 -1900 U/hr; digoxin, 0.25 mg daily; isosorbide dinitrate, 20 mg three times
each day; furosemide, 80 mg every 12 hr; and captopril, 25 mg every 8 hr. An echocar-
diogram and multigated radionuclide ventriculography scan verified an ejection fraction
of 15 percent, and the wall motion abnormalities noted previously on cardiac catheteriza-
tion at the time of angioplasty.
The patient underwent cardiac transplantation 23 days after his myocardial infarction.
On the day of transplantation, his BUN and creatinine were 25 mg/di and 1.0 mg/dl,
respectively. The cardiac bypass time was 2 hr 21 min, and the warm ischemia time ofthe
allograft (period between circulatory arrest of donor and commencement ofcold storage)
was 1 hr 20 min. Postoperatively, he was started on methylprednisolone, 125 mg given
intravenously every 8 hr, three doses; cyclosporine, 0.7 mg/kg/day administered by naso-
gastric tube; azathioprine, 1 mg/kg/day by naso-gastric tube, and OKT3 (anti-thymocyte
globulin) 5 mg given intravenously daily for 14 days. Subsequently, his steroid therapy
was tapered to prednisone, 1 mg/kg/day and the maintenance cyclosporine dose was grad-
ually increased according to ourprotocol to 4.3 mg/kg/day by the fourth postoperative day
(Figure 1).
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Figure 1: Serum creatinine, urine output and cyclosporine dose of the patient.
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He was also maintained on intravenous isoproterenol, 0.04 ,ug/kg/min; dopamine,
5-8 mg/kg/min; and epinephrine, 0.1 pg/kg/min for a total of4 days. Prophylactic periop-
erative antibiotics included cefamandole, oxacillin and erythromycin. He was transferred
to the cardiothoracic intensive care unit on ventilatory and IABP support. Systolic blood
pressure remained in the range of75-85 mm Hg for the first 12-18 hr postoperatively. On
the second post-operative day, systolic blood pressure improved to 100-110 mm Hg.
However, serum creatinine increased to 2.2 mg/dl on the first post-operative day followed
by arise to 3.6mg/dl on the second post-operative day. Urinalysis revealed only rare gran-
ular casts, while urine sodium was low at 10 meq/l. Forced diuresis with intravenous
bumetanide, 4 mg/hr, and chlorothiazide, 500 mg given intravenously every 8 hr, was ini-
tiated to maintain the central venous pressure below 15 cm H20. On the second post-oper-
ative day the patient was extubated and the IABP was removed. He was gradually weaned
off the isoproterenol and epinephrine. Systolic blood pressure remained in the range of
120-140 mm Hg. The dopamine was continued at 2-3 1ig/kg/min in an attempt to enhance
renal perfiision. The cyclosporine levels (whole blood) ranged 156-223 ng/ml during this
time. However, BUN and creatinine continued to increase despite optimal hemodynamics.
In addition, urine output, which had previously been adequate, dropped precipitously to
250 ml in 24 hr. Figure 1 shows the time course of his serum creatinine and urine output
in the first 17 days post-transplant. He also developed hyponatremia (131 meq/l), hyper-
kalemia (5.5 meq/l) and hyperphosphatemia (8.7 mg/dl). Acute hemodialysis was initiat-
ed on the 5th day after his transplant, at which time his BUN and serum creatinine were
111 mg/dl and 5.7 mg/dl, respectively. Bumetanide and chlorothiazide were subsequently
discontinued. Because of the renal failure, his cyclosporine was withheld for three days.
He continued torequire supportive hemodialysis on a nearly alternate day basis, for atotal
of 5 treatments. Other post-operative problems included paralytic ileus which resolved
spontaneously after 5 days. His urine output began to improve by the 9th postoperative
day, and cyclosporine therapy was reinstituted. By the 13th post-operative day, his urine
output was greater than 2000 ml/day and serum creatinine was decreasing. The rest ofhis
hospital course was relatively uncomplicated. He was discharged 23 days after his trans-
plant surgery, with a serum creatinine of 1.2 mg/dl on a stable cyclosporine dose.
DISCUSSION
Background
Acute renal failure is a common and important complication of cardiac transplanta-
tion. Various series have reported an overall incidence ofARF in the range of 0-30 per-
cent. However, differentcriteriaforpatient inclusion in these studies may explain the wide
variation in ARF incidence [1-5]. In addition, inclusion ofpatients with different degrees
of renal failure in these series further complicates analysis of data (Table 1). Also, most
series, with theexception ofthatby Greenberg et al. [1], do notprovide dataregarding the
number of patients requiring dialytic intervention. Greenberg and his colleagues noted
thatdialysis was required in 5 percent ofall post-transplantpatients. However, among the
post-transplant patients on cyclosporine, a higher percentage (9 percent) of patients
required dialysis. Acute dialytic intervention is not entirely benign and may result in tran-
sienthemodynamic instability, transientarrhythmiadue toelectrolyte shifts, and, although
controversial, possibly prolong time to full recovery ofrenal function because ofhypoten-
sion-induced tubular damage. Moderate renal insufficiency occurred in 25-46 percent of
patients after cardiac transplantation [1, 4]. It is important to note that the cyclosporine
doses used in these series are comparatively higher than what is used in current practice.
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Table 1: Incidence ofARF and renal dysfunction following cardiac transplantation
Ref No. of Immnuno- ARF/ Severe Moderate Definition ofARF/
patients suppression Renal Dysfunction Renal Dysfunction renal dysfunction
(Subgroups) (% ofpatients) (% ofpatients)
1 43 (Group 1) CslPred 12 58 ARF: Cr> 8 mg/dl, need for dialysis
41 (Group 2) Aza/Pred 0 34 moderate azotemia: Cr 2-8 mg/dl,
84 (total) 6 46 BUN 40-140 mg/di
2 17 (Group 1) AzaIATGIPred 0 NS ARF: Cr> 3 mg/dl + uremnia,
23 (Group 2) CslPred 22 BUN> 150, need for dialysis
7 (Group 3) Cs*/ATG/Pred 0
47 (total) I11
3 21 Cs*/ATGIPred 0 NS ARF: Cr> 2.5 mng/dl,
urine output < 1000 cc/day
4 61 Cs/AzaIATGIPred 21 25 severe renal dysfunction:
Cr> 3 mg/dl \
moderate renal dysfunction:
Cr 2-3 mg/dl
5 23 CslPred +1- Aza 30 NS severe iena dysfuinction: Cr> 3 mig/d
BUN> 100 mg/dl, inability to main-
tain urine output of I ml/kg/hr
*"Low-.dose" cyclosporine
Abbreviations: Cr - serum creatinine; Cs - cyclosporine; Pred - prednisone/steroids; Aza - azathio-
prine; ATG - antithymocyte globulin; NS - not stated
In contrast to heart transplantation, the reported incidence ofARF complicating open
heart surgery has varied from 1.5 percent to 7 percent [6-8]. In a recent report of 5,181
patients, the incidence of ARF (defined as oligoanuria, BUN greater than 84 mgldl, and
need for dialysis) was only 1.5 percent [6]. Prolonged aortic cross-clamp time and car-
diopulmonary bypass time were risk factors forARF in open heart surgery. To evaluate the
incidence ofARF in both types of procedures, Greenberg directly compared heart trans-
plantation to other open heart surgery requiring cardiopulmonary bypass [1]. ARF
occurred in 6 percent of all transplant patients, regardless of immunosuppression proto-
col. Remarkably, no episodes ofARF developed in the group of patients who underwent
open heart surgery. The overall incidence of moderate azotemia was 46 percent in the
transplant group, compared to 4 percent in the non-transplant group. All patients who
required dialysis eventually recovered renal function after an unspecified period of time.
One death occuffed; however, this was unrelated to renal causes.
Predisposition to renal failure in the transplant patients included the following factors
(Table 2): a serum creatinine greater than 2 mg/dl or a creatinine clearance less than 55
ml/min the year before transplant, any hospitalization before transplantation, and periop-
erative cardiovascular compromise [2, 5]. Our patient was hospitalized prior to transplan-
tation, and developed transient post-operative hypotension which required vasopressor
support (dopamine 5-8 pig/kg/min). These factors likely predisposed him to the develop-
ment of acute renal failure following transplantation.
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Table 2: Factors predisposing to ARF after cardiac transplantation
Serum creatinine > 2 mg/dl at time oftransplant
Creatinine clearance < 55 ml/min at time of transplant
Any hospitalization prior to transplantation
Perioperative cardiovascular compromise
Higher cyclosporine dose (?)
It is interesting to note that despite the higher incidence ofARF in heart transplants,
the mortality rates (20-29 percent) in the groups studied were very similar to each other
[1, 2, 5]. Deaths were unrelated to renal causes. This rate of mortality is significantly
lower than the mortality rates (50-89 percent) reported for patients with ARF following
non-transplant open heart surgery [6-8]. Although the exact cause ofthe disparity in mor-
tality rates is unclear, one possibility is better heart function postoperatively compared to
preoperatively, leading to a generalized improvement in organ perfusion. Also, heart-
transplant candidates usually have only single organ failure prior to surgery, are general-
ly younger with mean ages ranging from 41 to 52 yr [1, 3, 5] and are healthier than the
elderly diabetics with peripheral vascular disease who require cardiac surgery. Finally,
ARF in open-heart surgery patients usually accompanies other organ failure, a reflection
of the poor over-all status of the patient. In heart-transplant patients, ARF appears to be
more related to cyclosporine therapy than to the underlying condition of the patient.
Role ofcyclosporine
Cyclosporine is a well-known nephrotoxin used to modify immune tolerance in the
setting of organ transplantation. The proposed mechanisms for cyclosporine nephrotoxic-
ity include alteration in efferent sympathetic signals to the kidney, altered levels ofcircu-
lating catecholamines, loss of vasodilatory effects of prostanoids, and induction of renal
cortical vasospasm [9]. In addition, recent data suggest that the alteration in renal function
induced by cyclosporine may be related to endothelin-1, a potent endothelium-derived
vasoconstrictor and mitogenic peptide [10].
Most authors have noted a much higher incidence of ARF in patients treated with
cyclosporine as part oftheir immunosuppression regimen. ARF (Table 1) occurred in 12-
22 percent of cyclosporine-treated patients, but was absent in the azathioprine-treated
patients [1, 2]. Moderate renal dysfunction (Table 1) was seen in 58 percent of
cyclosporine-treated patients, as compared with 34 percent of azathioprine-treated
patients [1]. Moreover, acute nephrotoxicity is clearly dose-related. The high incidence of
ARFreported in these studies occurred with the use ofcyclosporine doses as high as 17.5
mg/kg/day forinduction, and experience with renal transplantation highlightthe dose-tox-
icity relationship [11]. Macris suggested that high risk patients, as defined by a pre-trans-
plant creatinine clearance below 55 ml/min, any hospitalization before transplant and peri-
operative cardiovascularcompromise, should not be treated with intravenous cyclosporine
as part ofinduction [5]. Other authors have used antithymocyte globulin and steroids with
very low doses ofcyclosporine for induction. The course ofthese patients was not com-
plicated by significant infection, rejection, orARF [2, 3]. As a result of increased recog-
nition for potential serious nephrotoxicity associated with cyclosporine in cardiac trans-
plantation, the currently recommended dosing regimens are associated with a lower inci-
dence ofARF. However, the aggressive use ofdiuretics postoperatively has enhanced the
renal toxicity associated withcyclosporine, in one surgeon's experience [see discussion in
ref. 5]. Despitereceiving a low dose ofcyclosporine initially forinduction, ourpatient still
465Cruz and Perazella: Renalfailure after heart transplant
developed ARF. As noted, other factors such as aggressive diuresis and hemodynamic
compromise, and use of vasopressor medications in the early postoperative period
increased the nephrotoxic actions ofcyclosporine.
Clinicalfeatures
The ARF typically develops within the first few days after transplantation (Table 3).
In Greenberg's series, a decrease in urine output heralded the occurrence of renal failure
[1, 11]. Oliguria persisted throughout the period ofrenal impairment. BUN and creatinine
peaked at 4-5 days post-operatively while recovery at 7-10 days was most often sponta-
neous after areduction in cyclosporine dose. Amarkedly elevated BUN to creatinine ratio,
low urine sodium (less than 10 meqfl), and inactive urine sediment suggest severe renal
hypoperfusion with intact tubular function. Hyperkalemia disproportionate to the degree
of renal impairment also occurs. Our patient demonstrated most of these abnormalities,
although the presence of a few granular casts in the urine suggest an additional compo-
nent of mild acute tubular necrosis. His renal function began to improve after the
cyclosporine doses were temporarily withheld.
Table 3: Clinical features ofARF after cardiac transplantation
Occurs within first 4 days following transplant
BUN, creatinine peaks at 4-5 days following transplant
Recovery after reduction in cyclosporine dose (usually)
Oliguria
Elevated BUN/creatinine ratio
Hyperkalemia disproportionate to azotemia
Low UNa (<10 meq/l) and FENa (<1%)
Inactive urine sediment
Lower mortality compared to ARF following other open heart surgery
These data suggest that a state of pre-renal azotemia, as seen in true volume deple-
tion or heart failure (effective volume depletion) develops in these patients. However, rel-
ative volume expansion, as indicated by higher body weights immediately after surgery,
and improved postoperative cardiac pump function make these causes of pre-renal
azotemia unlikely. It is more likely that inadequate levels of vasodilator substances to
maintain renal cortical blood flow, or potent vasoconstrictor effects of cyclosporine
explain this clinical picture. This short-lived nephrotoxicity occurs reproducibly, is dose-
related, and responds to discontinuation of cyclosporine [11]. However, other factors
undoubtedly contribute to and exacerbate the nephrotoxicity associated with cyclosporine
therapy in the cardiac transplant patient.
A protracted form of renal failure beyond 7-10 days occurs less frequently than the
early transient renal injury. Prolongation of ARF in bone-marrow and heart-transplant
patients whose course has been complicated by septicemia or surgery has been observed.
In addition, this phenomenon is also well-recognized in renal transplant patients. Failure
to withdraw cyclosporine under these circumstances has been associated with irreversible
renal failure [9].
Pathology
Although most of the literature on the pathology of cyclosporine nephrotoxicity
comes from renal transplant studies, the histologic appearance is apparently very similar.
466Cruz andPerazella: Renalfailure after heart transplant
There is vacuolization of the proximal tubular cells with destruction of apical microvilli.
Giant mitochondria, dilatation of the ergastoplasmic cistemae, and numerous lysosomes
are seen on electron microscopy. The arterioles exhibit small foci of fibrinoid parietal
necrosis, endothelial swelling and occasionally microthrombi. In later stages, this may
progress to a fibrous endarteritis. These vascular changes may result in ischemic retrac-
tion of the glomerulus. Otherwise, glomerular findings are typically minimal. The patho-
logic features ofcyclosporine nephrotoxicity are reviewed elsewhere [9, 12].
Management
At this time, the treatment ofARF in the heart-transplant patient is mainly support-
ive. Reduction of cyclosporine dose when possible, maintenance of euvolemia, and dia-
lytic intervention (intermittent or continuous) are the mainstays oftherapy. The potential
role of atrial natriuretic peptide (ANP)-like substances has also been studied [13-15].
Urodilatin is a polypeptide extracted from human urine and belongs to a family of natri-
uretic-vasorelaxant peptides found in the cardiac atria, one ofwhich is called CDD/ANP-
99-126. It is thought to have vasorelaxant effects on renal, pulmonary and coronary vas-
cular smooth muscle, and its effects are thought to be mediated by the natriuretic peptide
receptor with cGMP as its second messenger [16]. Like atrial natriuretic factor, it causes
preglomerular vasodilatation and efferent vasoconstriction, raising glomerular hydrostat-
ic pressure and increasing glomerular filtration rate. Its effects are more prominent in the
cortical glomerular arterioles. A continuous infusion ofurodilatin for 96 hr postoperative-
ly has resulted in maintenance ofnonoliguria, a lowerpeak BUN and creatinine compared
to historical controls (BUN 109 vs 155 mg/dl and creatinine 1.5 vs 2.9 mg/dl, respective-
ly), and decreased requirement for dialysis (6 percent vs 10 percent in controls) [13, 14].
Moreover, treatment with urodilatin in established renal failure in heart and liver trans-
plants has resulted in diuresis within a few hours of infusion [15].
Chronic cyclosporine nephrotoxicity
Late onset renal failure is not simply a continuation of early azotemia or incomplete
recovery of renal function. No correlation has been seen between peak creatinine in the
perioperative period and creatinine at 6, 12, or 24 months. This suggests that the early
form of renal dysfunction does not predispose to chronic nephrotoxicity. [17]
Furthermore, 3-7 percent of heart-transplant patients surviving more than two years have
been noted to progress to end-stage renal disease [17, 18]. This is likely the result of
cyclosporine associated chronic nephropathy. An extensive body of literature on chronic
cyclosporine effects on renal function in heart-transplant patients is available elsewhere
for review [17-19].
SUMMARY
ARF is a relatively frequent complication associated with heart transplantation.
Patients usually develop oligoanuria, laboratory features typical of pre-renal azotemia,
and a bland urine sediment. Cyclosporine plays a major etiologic role, and the ARF is
often dose-related. Poorpreoperative renal function andperioperative hemodynamic com-
promise also predispose patients to the development of ARF. Current management is
entirely supportive; aminority ofpatients requiredialysis. The use ofANP-like substances
in the prevention and treatment ofARF after heart and liver transplantation has been stud-
ied, and appears to show promise. Interestingly, the mortality of these patients is lower
than that ofpatients who develop ARF after other cardiac surgery.
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